#TREATMENT ACTION CAMPAIGN ZACC TRIAL#
Preventing mother-to-child transmission Ī single dose of nevirapine given to both mother and child reduced the rate of HIV transmission by almost 50% compared with a very short course of zidovudine (AZT) prophylaxis, in a clinical trial in Uganda. These guidelines include dosing algorithms for as young as newborn babies. Nevirapine may also form a useful component of salvage regimens after virological failure, usually in combination with one or more PIs as well as nucleotide reverse transcriptase inhibitor (NRTIs), especially in those who have not previously taken an NNRTI.ĭosing in children is based on body surface area (BSA), however, weight-based dosing algorithms have been released. Īlthough concerns have been raised about nevirapine-based regimens in those starting therapy with high viral load or low CD4 count, some analyses suggest that nevirapine may be effective in this group of people. This drug is generally only to be considered for use if the CD4 cell count is very low. Some clinical trials have demonstrated comparable HIV suppression with nevirapine-based regimens to that achieved with regimens based on a protease inhibitor (PI) or efavirenz. Nevirapine in triple combination therapy has been shown to suppress viral load effectively when used as initial antiretroviral therapy ( i.e., in antiretroviral-naive patients). Monotherapy with nevirapine is not indicated due to rapid emergence of resistance.
Nevirapine is used in people six years of age and older infected with HIV-1 as part of combination antiretroviral treatment (ART or cART). 1.1 Preventing mother-to-child transmission.
0 kommentar(er)
